Ceapro Inc. (CRPOF)
For informational purposes only. Not financial advice. Analysis by Sedat Aydin, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Ceapro Inc. (CRPOF) with AI Score 46/100 (Weak). Ceapro Inc. is a biotechnology company focused on developing and marketing health and wellness products derived from plant extracts. Market cap: 0, Sector: Healthcare.
Last analyzed: Mar 17, 2026Ceapro Inc. (CRPOF) Healthcare & Pipeline Overview
Ceapro Inc. is a biotechnology company specializing in the development and commercialization of plant-derived active ingredients for the healthcare and cosmeceutical industries. With proprietary extraction technologies, Ceapro focuses on oat beta glucan and avenanthramides, targeting markets in the United States, Germany, China, and Canada.
Investment Thesis
Ceapro Inc. presents a speculative investment opportunity within the biotechnology sector, driven by its proprietary extraction technologies and focus on plant-derived active ingredients. The company's potential lies in the growing demand for natural and sustainable ingredients in the healthcare and cosmetic industries. However, with a negative P/E ratio of -3.74 and a negative profit margin of -48.9%, the company's financial performance raises concerns. Key growth catalysts include successful commercialization of its active ingredients and expansion into new markets. Investors should carefully consider the risks associated with the company's financial performance and competitive landscape. The company's beta of 1.38 suggests higher volatility compared to the market.
Based on FMP financials and quantitative analysis
Key Highlights
- Market Cap of $0.01B indicates a small-cap company with potential for growth but also higher risk.
- P/E Ratio of -3.74 reflects negative earnings, suggesting the company is currently not profitable.
- Gross Margin of 37.0% indicates the percentage of revenue exceeding the cost of goods sold.
- Beta of 1.38 suggests the stock is more volatile than the market average.
- Profit Margin of -48.9% indicates significant losses relative to revenue.
Competitors & Peers
Strengths
- Proprietary extraction technologies
- Focus on plant-derived active ingredients
- Presence in multiple geographic markets
- Two distinct business segments (Active Ingredient and Cosmeceutical)
Weaknesses
- Negative P/E ratio and profit margin
- Small market capitalization
- Reliance on online sales for cosmeceutical products
- Limited financial resources
Catalysts
- Upcoming: Potential regulatory approvals for new active ingredients.
- Ongoing: Expansion of online sales and marketing efforts.
- Ongoing: Development of new cosmeceutical products.
- Upcoming: Announcement of strategic partnerships with other companies.
Risks
- Potential: Intense competition in the biotechnology industry.
- Potential: Regulatory scrutiny and compliance requirements.
- Ongoing: Fluctuations in raw material prices.
- Ongoing: Negative P/E ratio and profit margin.
- Potential: Economic downturns affecting consumer spending.
Growth Opportunities
- Expansion into New Markets: Ceapro Inc. has the opportunity to expand its geographic reach beyond its current markets in the United States, Germany, China, and Canada. Targeting new markets in Asia and Europe could drive revenue growth and increase market share. The global market for natural ingredients in cosmetics is projected to reach $36 billion by 2027, providing a significant opportunity for Ceapro to capitalize on its plant-derived active ingredients. This expansion could occur within the next 2-3 years.
- Development of New Products: Ceapro Inc. can invest in research and development to create new products based on its proprietary extraction technologies. Developing new active ingredients and formulations could attract new customers and increase revenue. The market for anti-aging products is expected to reach $83.2 billion by 2027, offering a significant opportunity for Ceapro to expand its cosmeceutical product line. This development could begin within the next year.
- Strategic Partnerships: Ceapro Inc. can form strategic partnerships with other companies in the healthcare and cosmetic industries to expand its distribution network and access new markets. Partnering with established players could accelerate growth and reduce risk. The global market for healthcare partnerships is estimated at $1.2 trillion, indicating substantial opportunities for collaboration. These partnerships could be established within the next 1-2 years.
- Increased Online Sales: Ceapro Inc. can focus on increasing its online sales through its website and other e-commerce platforms. Enhancing its online marketing efforts and improving the customer experience could drive revenue growth. The global e-commerce market is projected to reach $6.5 trillion in 2023, providing a significant opportunity for Ceapro to expand its online sales. This initiative can be implemented immediately.
- Licensing of Technology: Ceapro Inc. can license its proprietary extraction technologies to other companies in the healthcare and cosmetic industries. Licensing its technology could generate revenue and expand its market reach without requiring significant investment. The global market for technology licensing is estimated at $400 billion, indicating substantial opportunities for Ceapro to monetize its intellectual property. Licensing agreements could be pursued within the next year.
Opportunities
- Expansion into new geographic markets
- Development of new products and formulations
- Strategic partnerships with other companies
- Increased online sales and marketing efforts
Threats
- Intense competition in the biotechnology industry
- Regulatory scrutiny and compliance requirements
- Fluctuations in raw material prices
- Economic downturns affecting consumer spending
Competitive Advantages
- Proprietary extraction technologies provide a competitive advantage.
- Focus on plant-derived active ingredients aligns with consumer demand for natural products.
- Established presence in the healthcare and cosmetic industries.
About CRPOF
Ceapro Inc., established in 1997 and headquartered in Edmonton, Canada, is a biotechnology company dedicated to the development and marketing of health and wellness products and technologies based on plant extracts. The company operates through two primary segments: Active Ingredient Product Technology Industry and Cosmeceutical Industry. The Active Ingredient Product Technology Industry segment focuses on developing proprietary extraction technologies and applying these technologies to the production, development, and commercialization of active ingredients. Key products include oat beta glucan and avenanthramides, derived from oats and other renewable plant resources, which are utilized in the healthcare and cosmetic industries. The Cosmeceutical Industry segment is involved in the development and commercialization of anti-aging products derived from natural active ingredients. These products are sold directly to end-users primarily through online website sales and through select natural products stores. Ceapro's geographic reach extends to the United States, Germany, China, Canada, and other international markets. The company aims to leverage its proprietary technologies to create value-added products in the health and wellness space.
What They Do
- Develop and market health and wellness products.
- Specialize in plant extract-based products.
- Operate in the Active Ingredient Product Technology Industry.
- Operate in the Cosmeceutical Industry.
- Develop proprietary extraction technologies.
- Commercialize active ingredients like oat beta glucan and avenanthramides.
- Produce anti-aging products derived from natural active ingredients.
Business Model
- Develop and sell active ingredients to healthcare and cosmetic companies.
- Develop and sell cosmeceutical products directly to consumers through online sales.
- Generate revenue through the sale of plant-derived active ingredients and cosmeceutical products.
Industry Context
Ceapro Inc. operates within the biotechnology industry, which is characterized by rapid innovation and intense competition. The market for natural and sustainable ingredients in healthcare and cosmetics is growing, driven by consumer demand for cleaner and more environmentally friendly products. Ceapro competes with other biotechnology companies, including ABDXF, AMHV, EIGRQ, LVCLY, and NOXOF, that are also developing and marketing plant-derived active ingredients. The industry is subject to regulatory scrutiny and requires significant investment in research and development.
Key Customers
- Healthcare companies that use active ingredients in their products.
- Cosmetic companies that use active ingredients in their products.
- End-users who purchase cosmeceutical products directly through online sales.
Financials
Chart & Info
Ceapro Inc. (CRPOF) stock price: Price data unavailable
Latest News
-
Stocks That Hit 52-Week Lows On Monday
· Dec 2, 2019
Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CRPOF.
Price Targets
Wall Street price target analysis for CRPOF.
MoonshotScore
What does this score mean?
The MoonshotScore rates CRPOF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Gilles R. Gagnon
CEO
Gilles R. Gagnon serves as the CEO of Ceapro Inc. His background includes extensive experience in the biotechnology and pharmaceutical industries. He has held various leadership positions in companies focused on drug development and commercialization. Gagnon's expertise spans strategic planning, business development, and financial management. He is known for his ability to drive growth and innovation in the healthcare sector. His educational background includes advanced degrees in business and science.
Track Record: Under Gilles R. Gagnon's leadership, Ceapro Inc. has focused on expanding its product portfolio and strengthening its market position. Key achievements include the development and commercialization of new active ingredients and cosmeceutical products. He has also overseen the expansion of the company's geographic reach and the establishment of strategic partnerships. His tenure has been marked by a commitment to innovation and sustainable growth.
CRPOF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Ceapro Inc. may not meet the minimum financial or disclosure requirements of the higher tiers (OTCQX and OTCQB). Companies in this tier often have limited trading volume and may be subject to greater price volatility. Investing in companies on the OTC Other tier carries significant risks due to the lack of regulatory oversight and the potential for fraud or manipulation. This tier is also known as the Pink Open Market.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited regulatory oversight on the OTC Other tier increases the risk of fraud and manipulation.
- Lack of financial transparency due to limited disclosure requirements.
- Low trading volume and liquidity can lead to price volatility.
- Higher potential for delisting or trading suspension.
- Increased difficulty in obtaining accurate and reliable information about the company.
- Verify the company's registration and compliance with regulatory requirements.
- Obtain and review audited financial statements.
- Assess the company's management team and their track record.
- Evaluate the company's business model and competitive landscape.
- Understand the company's capital structure and potential dilution.
- Review any legal or regulatory issues facing the company.
- Consult with a qualified financial advisor.
- The company has been in operation since 1997.
- Ceapro Inc. has a portfolio of proprietary extraction technologies.
- The company has a presence in multiple geographic markets.
- Ceapro Inc. has a CEO with experience in the biotechnology industry.
CRPOF Healthcare Stock FAQ
What does Ceapro Inc. do?
Ceapro Inc. is a biotechnology company that develops, manufactures, and markets active ingredients and cosmeceutical products derived from plant extracts. The company operates through two segments: Active Ingredient Product Technology Industry and Cosmeceutical Industry. The Active Ingredient segment focuses on producing ingredients like oat beta glucan for the healthcare and cosmetic industries, while the Cosmeceutical segment develops and sells anti-aging products directly to consumers, primarily through online channels. Ceapro's core competency lies in its proprietary extraction technologies that enable the production of high-value ingredients from renewable plant resources.
What do analysts say about CRPOF stock?
As of 2026-03-17, there is no readily available analyst consensus on CRPOF stock, likely due to its OTC listing and small market capitalization. Key valuation metrics, such as the negative P/E ratio, indicate that the company is currently not profitable. Growth considerations revolve around the successful commercialization of its active ingredients, expansion into new markets, and the development of new products. Investors should conduct their own thorough research and consider the risks associated with investing in a small-cap, OTC-listed company in the biotechnology sector.
What are the main risks for CRPOF?
The main risks for Ceapro Inc. include intense competition in the biotechnology and cosmeceutical industries, regulatory scrutiny and compliance requirements, fluctuations in raw material prices, and the company's current lack of profitability. As an OTC-listed company, CRPOF also faces risks related to limited liquidity, potential for price volatility, and reduced transparency compared to companies listed on major exchanges. Furthermore, the company's reliance on online sales for its cosmeceutical products makes it vulnerable to changes in consumer behavior and competition from other online retailers.
What are the key factors to evaluate for CRPOF?
Ceapro Inc. (CRPOF) currently holds an AI score of 46/100, indicating low score. Key strength: Proprietary extraction technologies. Primary risk to monitor: Potential: Intense competition in the biotechnology industry.. This is not financial advice.
How frequently does CRPOF data refresh on this page?
CRPOF prices update in real time during U.S. market hours (9:30 AM-4:00 PM ET, weekdays). Fundamentals refresh after quarterly or annual filings. Analyst ratings and AI insights update daily. News is aggregated continuously from financial sources.
What has driven CRPOF's recent stock price performance?
Recent price movement in Ceapro Inc. (CRPOF) can be influenced by earnings results, analyst revisions, sector rotation, and broader market sentiment. Notable catalyst: Proprietary extraction technologies. Check the News and Technical Analysis tabs for the latest drivers. Past performance does not predict future results.
Should investors consider CRPOF overvalued or undervalued right now?
Determining whether Ceapro Inc. (CRPOF) is overvalued or undervalued requires examining multiple metrics. Compare valuation ratios (P/E, P/S, EV/EBITDA) against sector peers for a comprehensive view.
What research should beginners do before buying CRPOF?
Before investing in Ceapro Inc. (CRPOF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be less reliable than exchange-listed data.